Targeting Neuropathogenesis of Altered Mental Status to Improve Survival in Cryptococcal Meningitis
Project Number5K23NS122601-04
Former Number1K23NS122601-01
Contact PI/Project LeaderABASSI, MAHSA
Awardee OrganizationUNIVERSITY OF MINNESOTA
Description
Abstract Text
Project Summary / Abstract
Dr. Mahsa Abassi is an Assistant Professor of Medicine in the Division of Infectious Diseases at the
University of Minnesota. Over the past six years, she has been engaged in clinical research, focusing on HIV-
related neuroinfections in Uganda. Her long-term objective is to become an independent clinical researcher
with an emphasis on improving outcomes in neuroinfections. Her career development plan proposes mentored
training in: 1) neurologic techniques (EEGs, neuroradiology, and neurocognitive assessment), 2) laboratory
techniques related to metabolomics applications, and 4) biostatistics with an emphasis of analyzing
metabolites in biologic samples.
Research: Cryptococcal meningitis accounts for 15% of HIV/AIDS-related deaths globally and is the most
common cause of adult meningitis in Africa. Altered mental status (ranging from delirium to coma) at the time
of cryptococcal meningitis diagnosis is consistently an independent predictor of increased mortality. Despite
repeated studies confirming this strong association between altered mental status and death, there is a
fundamental lack of understanding into the exact neurological abnormalities leading to acute altered mental
status, its contributions to increased mortality, and the best practices for management.
The objective of this proposal is to identify the neurological abnormalities that contribute to altered mental
status and to understand how this contributes to increased cryptococcal mortality. The overarching hypothesis
is that cryptococcal meningitis with its increased intracranial pressure leads to cerebral hypoxia, abnormal
electrical activity, and biochemical changes in the central nervous system (CNS) that can be detected through
brain metabolite CSF analysis and enhanced clinical monitoring with cerebral oximetry and EEGs. This
proposal aims to: 1) determine if HIV-infected persons with cryptococcal meningitis presenting with altered
mental status (Glasgow Coma Scale (GCS) <15) at diagnosis have measurable underlying neurological
abnormalities and impairments in cerebral energy metabolism (i.e. insufficient oxidative metabolism) as
compared to persons with normal mental status (GCS=15); and 2) determine if implementation of standardized
clinical interventions can reverse neurological abnormalities and improve cerebral energy metabolism within 3
days of diagnosis, and reduce 30-day mortality in HIV-infected persons with cryptococcal meningitis presenting
with altered mental status (GCS<15). Results of the above aims will shed light into previously unknown
pathophysiologic mechanisms that lead to altered mental status in cryptococcal meningitis. The training in
neuroinfections, metabolomics applications, and biostatistics that Dr. Abassi will obtain will inform future
proposals dedicated to understanding the neuropathology of various neuroinfections and finding evidence-
based interventions dedicated to improving survival.
Public Health Relevance Statement
Project Narrative
In HIV-associated cryptococcal meningitis, altered mental status is a common clinical manifestation and
is associated with a significant increase in mortality. There is a considerable lack of understanding as to the
exact neurological abnormalities leading to the development of acute altered mental status in cryptococcal
meningitis. The objective of this study is to identify the underlying neurological abnormalities that result in the
development of altered mental status during cryptococcal meningitis and to identify clinical interventions to
reverse these neurological abnormalities and improve survival.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AccountingAcquired Immunodeficiency SyndromeAcuteAddressAdultAfricaAfrica South of the SaharaAnticonvulsantsBiochemicalBiologicalBiological Response Modifier TherapyBiometryBrainCell RespirationCentral Nervous SystemCentral Nervous System InfectionsCerebral HypoxiaCerebrospinal FluidCerebrumCessation of lifeClinicalClinical ResearchComaCommunicable DiseasesCongenital neurologic anomaliesCryptococcal MeningitisCryptococcusDataDedicationsDeliriumDetectionDevelopmentDevelopment PlansDiagnosisEarly identificationElectroencephalographyEnergy MetabolismEvidence based interventionExcess MortalityFunctional disorderFutureGlasgow Coma ScaleGlucoseGoalsGrantGuidelinesHIVHIV/AIDSImpairmentInfectionInternationalInterventionIntracranial HypertensionLaboratoriesLeukocytesLightMeasurableMedicineMeningitisMentorsMentorshipMinnesotaMonitorNeurocognitiveNeurologicNeuropathogenesisOxygen saturation measurementPathogenesisPathologyPatientsPersonsPractice ManagementPyruvateReportingResearchResearch PersonnelSamplingSeizuresStandardizationSupportive careTechniquesTestingTimeTrainingUgandaUniversitiesantiretroviral therapycareer developmentexperienceimprovedimproved outcomeinnovationinsightlaboratory experiencelow income countrymental statemetabolomicsmortalityneuropathologyprofessortherapy design
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
555917996
UEI
KABJZBBJ4B54
Project Start Date
16-August-2021
Project End Date
30-June-2026
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$201,420
Direct Costs
$186,500
Indirect Costs
$14,920
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$201,420
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K23NS122601-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K23NS122601-04
Patents
No Patents information available for 5K23NS122601-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K23NS122601-04
Clinical Studies
No Clinical Studies information available for 5K23NS122601-04
News and More
Related News Releases
No news release information available for 5K23NS122601-04
History
No Historical information available for 5K23NS122601-04
Similar Projects
No Similar Projects information available for 5K23NS122601-04